Benzinga | Jul 13, 2021 08:16AM EDT

Hoth Therapeutics Announces Confirmatory Results From In Vivo Model Of HT-003 As Potential Treatment Against Acne; Model Showed HT-003 'reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology'

Hoth Therapeutics, Inc. (NASDAQ:HOTH), a patient-focused biopharmaceutical company, announced today that its HT-003 group of assets has yielded positive results in an in vivo acne therapeutic model. The model showed that HT-003 reduces the expression of toll-like receptor 2 (TLR2), one of the most critical pathways for acne pathophysiology. The study also showed that HT-003 reduces the expression of numerous cytokines critical for acne pathophysiology that are also relevant therapeutic markers for other inflammatory-driven skin diseases.